Home > Healthcare > Medical Devices > Diagnostic Devices > Prostate-Specific Antigen Test Market

Prostate-Specific Antigen Test Market Trends

Report ID: GMI7136
Published Date: Oct 2023
Report Format: PDF

Download Free Sample

Prostate-Specific Antigen Test Market Trends

The prostate-specific antigen (PSA) test industry is subject to several key factors, including technological advancements, evolving demographics, and shifting healthcare protocols. These dynamics significantly influence the demand for, accessibility of, and adoption of PSA testing.

A rising trend in managing low-risk prostate cancer cases is the adoption of active surveillance. This approach, in contrast to immediate treatment, involves rigorous monitoring to determine the necessity of intervention.
The market is continuously witnessing the development of more precise and sophisticated PSA testing methodologies. These innovations are geared toward reducing false positives, enhancing diagnostic accuracy, and providing a deeper understanding of prostate health.
Additionally, Magnetic resonance imaging (mpMRI) is increasingly being employed in conjunction with PSA testing for visualizing the prostate gland. It plays a pivotal role in identifying and pinpointing suspicious areas, thereby guiding biopsy decisions, and significantly enhancing diagnostic accuracy.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Prostate-specific antigen test industry size was USD 3.9 billion in 2022 and is estimated to reach USD 8.8 billion by 2032 due to the ongoing research in the field of prostate cancer diagnostics and therapy.

The hospitals end-use segment was USD 1.5 billion in 2022 due to the surge in patient awareness regarding the importance of regular prostate cancer screening.

North America prostate-specific antigen test industry was worth USD 1.5 billion in revenue in 2022 due to demographic shifts, increased awareness, and rising technological advancements in the region.

Abbott Laboratories Inc., AdvaCare Pharma, Bayer AG, Bio-Rad Laboratories, Inc., Beckman Coulter, Inc., GE HealthCare, Abcam plc., Lomina AG, and Laboratory Corporation of America Holdings are some of the major prostate-specific antigen test companies.